

**Roger Newton**  
**Senior Vice President and Director, Esperion Therapeutics,**  
**a Division of Pfizer Global Research & Development**



Dr. Newton has worked 25 years in the pharmaceutical and life sciences industries. He most recently was senior vice president of Pfizer Global Research and Development and director at Esperion Therapeutics, a Pfizer Inc. company. He was cofounder, president and chief executive officer of Ann Arbor, Mich.-based Esperion Therapeutics Inc. (NASDAQ:ESPR), a biopharmaceutical company founded in July 1998. Esperion was dedicated to the discovery and development of pharmaceutical products for the treatment of cardiovascular diseases with a new treatment approach called "HDL Therapy." Pfizer purchased Esperion for \$1.3 billion in February 2004.

Before founding Esperion, Newton worked for Warner-Lambert/Parke-Davis (now Pfizer) from 1981-1998. As a distinguished scientist and chairman of the Atherosclerosis Drug Discovery Team, he co-discovered and was the product champion of what is now the most prescribed cholesterol-reducing drug in the world, atorvastatin, now known as Lipitor.

His research interests the past 30 years have focused on the nutritional and pharmacological regulation of cholesterol and lipoprotein metabolism as they relate to atherosclerosis and vascular diseases. Newton is also an Adjunct Associate Professor in the Department of Pharmacology at the University of Michigan Medical School. He has co-authored nearly 100 peer-reviewed articles and chapters during his research career. Newton completed a postdoctoral fellowship in the National Institutes of Health-sponsored Specialized Center of Research in Atherosclerosis at the University of California, San Diego.

He has a Ph.D. in nutrition from the University of California Davis, a master's degree in nutritional biochemistry from the University of Connecticut and a bachelor's degree in biology from Lafayette College in Easton, Pa.

Newton is past chairman of the Great Lakes Venture Quest and a former member of the Michigan Life Science Corridor Steering Committee from 1999-2003. He is currently director on the board of Rubicon Genomics and Resverlogix Inc., a member of the University of Michigan Cardiovascular Center National Advisory Board, Biotech Business Associates Advisory Board, and the University Musical Society Board.

Through his philanthropic interests and the Esperance Family Foundation, he and his family are active supporters of non-profit organizations focusing on human potential, social justice, health and the environment. He and his wife have three children and live in Ann Arbor, Mich.